198 related articles for article (PubMed ID: 35677046)
1. Systemic Immune Dysregulation in Early Breast Cancer Is Associated With Decreased Plasma Levels of Both Soluble Co-Inhibitory and Co-Stimulatory Immune Checkpoint Molecules.
Rapoport BL; Steel HC; Hlatshwayo N; Theron AJ; Meyer PWA; Nayler S; Benn CA; Smit T; Kwofie LLI; Heyman L; Anderson R
Front Immunol; 2022; 13():823842. PubMed ID: 35677046
[TBL] [Abstract][Full Text] [Related]
2. Dysregulation of systemic soluble immune checkpoints in early breast cancer is attenuated following administration of neoadjuvant chemotherapy and is associated with recovery of CD27, CD28, CD40, CD80, ICOS and GITR and substantially increased levels of PD-L1, LAG-3 and TIM-3.
Rapoport BL; Steel HC; Benn CA; Nayler S; Smit T; Heyman L; Theron AJ; Hlatshwayo N; Kwofie LLI; Meyer PWA; Anderson R
Front Oncol; 2023; 13():1097309. PubMed ID: 37064132
[TBL] [Abstract][Full Text] [Related]
3. Systemic levels of the soluble co-inhibitory immune checkpoints, CTLA-4, LAG-3, PD-1/PD-L1 and TIM-3 are markedly increased in basal cell carcinoma.
Malinga NZ; Siwele SC; Steel HC; Kwofie LLI; Meyer PWA; Smit T; Anderson R; Rapoport BL; Kgokolo MCM
Transl Oncol; 2022 May; 19():101384. PubMed ID: 35255355
[TBL] [Abstract][Full Text] [Related]
4. Soluble immune checkpoint molecules in patients with antineutrophil cytoplasmic antibody-associated vasculitis.
Pyo JY; Yoon T; Ahn SS; Song JJ; Park YB; Lee SW
Sci Rep; 2022 Dec; 12(1):21319. PubMed ID: 36494415
[TBL] [Abstract][Full Text] [Related]
5. Patients With Microscopic Colitis Have Altered Levels of Inhibitory and Stimulatory Biomarkers in Colon Biopsies and Sera Compared to Non-inflamed Controls.
Lushnikova A; Bohr J; Wickbom A; Münch A; Sjöberg K; Hultgren O; Wirén A; Hultgren Hörnquist E
Front Med (Lausanne); 2021; 8():727412. PubMed ID: 34722568
[No Abstract] [Full Text] [Related]
6. T-cell responses against CD19+ pediatric acute lymphoblastic leukemia mediated by bispecific T-cell engager (BiTE) are regulated contrarily by PD-L1 and CD80/CD86 on leukemic blasts.
Feucht J; Kayser S; Gorodezki D; Hamieh M; Döring M; Blaeschke F; Schlegel P; Bösmüller H; Quintanilla-Fend L; Ebinger M; Lang P; Handgretinger R; Feuchtinger T
Oncotarget; 2016 Nov; 7(47):76902-76919. PubMed ID: 27708227
[TBL] [Abstract][Full Text] [Related]
7. Prognostic value of immune checkpoint molecules in breast cancer.
Fang J; Chen F; Liu D; Gu F; Chen Z; Wang Y
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32602545
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Chemoradiotherapy Changes the Landscape of Soluble Immune Checkpoint Molecules in Patients With Locally Advanced Rectal Cancer.
Liu C; Wang P; Sun Y; Dou X; Hu X; Zou W; Sun Y; Hu Q; Yue J
Front Oncol; 2022; 12():756811. PubMed ID: 35530332
[TBL] [Abstract][Full Text] [Related]
9. Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma.
Kgokolo MCM; Malinga NZ; Steel HC; Meyer PWA; Smit T; Anderson R; Rapoport BL
Transl Oncol; 2024 Apr; 42():101867. PubMed ID: 38308919
[TBL] [Abstract][Full Text] [Related]
10. Soluble Immune Checkpoint-Related Proteins in Blood Are Associated With Invasion and Progression in Non-Small Cell Lung Cancer.
Wang Q; He Y; Li W; Xu X; Hu Q; Bian Z; Xu A; Tu H; Wu M; Wu X
Front Immunol; 2022; 13():887916. PubMed ID: 35874720
[TBL] [Abstract][Full Text] [Related]
11. Peripheral cytokine levels as predictive biomarkers of benefit from immune checkpoint inhibitors in cancer therapy.
Ji S; Chen H; Yang K; Zhang G; Mao B; Hu Y; Zhang H; Xu J
Biomed Pharmacother; 2020 Sep; 129():110457. PubMed ID: 32887027
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint molecules B7-H6 and PD-L1 co-pattern the tumor inflammatory microenvironment in human breast cancer.
Cherif B; Triki H; Charfi S; Bouzidi L; Kridis WB; Khanfir A; Chaabane K; Sellami-Boudawara T; Rebai A
Sci Rep; 2021 Apr; 11(1):7550. PubMed ID: 33824367
[TBL] [Abstract][Full Text] [Related]
13. Elevated Levels of Soluble CTLA-4, PD-1, PD-L1, LAG-3 and TIM-3 and Systemic Inflammatory Stress as Potential Contributors to Immune Suppression and Generalized Tumorigenesis in a Cohort of South African Xeroderma Pigmentosum Patients.
Kgokolo MCM; Anderson K; Siwele SC; Steel HC; Kwofie LLI; Sathekge MM; Meyer PWA; Rapoport BL; Anderson R
Front Oncol; 2022; 12():819790. PubMed ID: 35223501
[TBL] [Abstract][Full Text] [Related]
14. Soluble immune checkpoint-related proteins as predictors of tumor recurrence, survival, and T cell phenotypes in clear cell renal cell carcinoma patients.
Wang Q; Zhang J; Tu H; Liang D; Chang DW; Ye Y; Wu X
J Immunother Cancer; 2019 Nov; 7(1):334. PubMed ID: 31783776
[TBL] [Abstract][Full Text] [Related]
15. Immune Checkpoint Blockade in Breast Cancer Therapy.
Bu X; Yao Y; Li X
Adv Exp Med Biol; 2017; 1026():383-402. PubMed ID: 29282694
[TBL] [Abstract][Full Text] [Related]
16. Co-stimulatory agonists: An insight into the immunotherapy of cancer.
Pourakbari R; Hajizadeh F; Parhizkar F; Aghebati-Maleki A; Mansouri S; Aghebati-Maleki L
EXCLI J; 2021; 20():1055-1085. PubMed ID: 34267616
[TBL] [Abstract][Full Text] [Related]
17. Breast Cancer Cells and PD-1/PD-L1 Blockade Upregulate the Expression of PD-1, CTLA-4, TIM-3 and LAG-3 Immune Checkpoints in CD4
Saleh R; Toor SM; Khalaf S; Elkord E
Vaccines (Basel); 2019 Oct; 7(4):. PubMed ID: 31614877
[No Abstract] [Full Text] [Related]
18. Correlation between the immune checkpoints and EMT genes proposes potential prognostic and therapeutic targets in ESCC.
Mahmoudian RA; Mozhgani S; Abbaszadegan MR; Mokhlessi L; Montazer M; Gholamin M
J Mol Histol; 2021 Jun; 52(3):597-609. PubMed ID: 33884540
[TBL] [Abstract][Full Text] [Related]
19. Platelet-expressed immune checkpoint regulator GITRL in breast cancer.
Zhou Y; Heitmann JS; Clar KL; Kropp KN; Hinterleitner M; Engler T; Koch A; Hartkopf AD; Zender L; Salih HR; Maurer S; Hinterleitner C
Cancer Immunol Immunother; 2021 Sep; 70(9):2483-2496. PubMed ID: 33538861
[TBL] [Abstract][Full Text] [Related]
20. The Expression Pattern and Clinical Significance of the Immune Checkpoint Regulator VISTA in Human Breast Cancer.
Xie X; Zhang J; Shi Z; Liu W; Hu X; Qie C; Chen W; Wang Y; Wang L; Jiang J; Liu J
Front Immunol; 2020; 11():563044. PubMed ID: 33250890
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
